share_log

AstraZeneca | 6-K: Datopotamab Deruxtecan Biologics License Application Accepted in the Us for Patients with Previously Treated Metastatic HR-Positive, HER2-Negative Breast Cancer

SEC announcement ·  Apr 2 07:59
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more